Author

Malin Hultcrantz

MD PhD, Memorial Sloan Kettering Cancer Center - Cited by 4,190 - Hematology - Multiple Myeloma - Myeloproliferative Neoplasms

Biography

Malin Hultcrantz, belonging to Department of Hematology, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden. Interested in the field of Acute lung injury; Acute respiratory distress syndrome.
Title
Cited by
Year
GPRC5D-targeted CAR T cells for myeloma
S Mailankody, SM Devlin, J Landa, K Nath, C Diamonte, EJ Carstens, ...New England Journal of Medicine 387 (13), 1196-1206, 2022202
62
2022
Defining new reference intervals for serum free light chains in individuals with chronic kidney disease: results of the iStopMM study
TE Long, OS Indridason, R Palsson, S Rognvaldsson, TJ Love, ...Blood Cancer Journal 12 (9), 133, 2022202
15
2022
Sustained minimal residual disease negativity in multiple myeloma is associated with stool butyrate and healthier plant-based diets
UA Shah, KH Maclachlan, A Derkach, M Salcedo, K Barnett, J Caple, ...Clinical cancer research 2 (23), 5149-5155, 2022202
8
2022
Prevalence of smoldering multiple myeloma based on nationwide screening
S Thorsteinsdóttir, GK Gíslason, T Aspelund, S Rögnvaldsson, ...Nature medicine 29 (2), 46-42, 2023202
7
2023
Pregnancy and childbirth outcomes in women with myeloproliferative neoplasms—a nationwide population-based study of 342 pregnancies in Sweden
AR Landtblom, TML Andersson, ALV Johansson, SB Wendel, ...Leukemia 36 (10), 2461-246, 2022202
7
2022
Prevalence of MGUS Is High in the Istopmm Study but the Prevalence of IgA MGUS Does Not Increase with Age in the Way Other Immunoglobulin Subtypes Do
TJ Love, S Rögnvaldsson, S Thorsteinsdottir, T Aspelund, ER Reed, ...Blood 140 (Supplement 1), 26-28, 2022202
5
2022
Belantamab mafodotin in patients with relapsed/refractory multiple myeloma, a real-world single center experience
M Hultcrantz, A Derkach, H Hassoun, N Korde, KH Maclachlan, ...Blood 10 (Supplement 1), 726-728, 2022202
4
2022
Single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: Final analysis of the DREAMM-2 Trial
AK Nooka, A Cohen, HC Lee, AZ Badros, A Suvannasankha, N Callander, ...Blood 10 (Supplement 1), 7301-7303, 2022202
4
2022
Carfilzomib, lenalidomide and dexamethasone (KRd) vs bortezomib, lenalidomide, and dexamethasone (VRd) As induction therapy in newly diagnosed high-risk multiple myeloma
C Tan, D Nemirovsky, A Derkach, M Hultcrantz, H Hassoun, S Mailankody, ...Blood 140 (Supplement 1), 1817-1819, 2022202
3
2022
Systemic light chain amyloidosis, version 2.2023, NCCN clinical practice guidelines in oncology
Systemic light chain amyloidosis, version .03, NCCN clinical practice guidelines in oncologySK Kumar, NS Callander, K Adekola, LD Anderson, M Baljevic, ...Journal of the National Comprehensive Cancer Network 1 (1), 67-81, 030
2
2023
Belantamab Mafodotin (Belamaf) for Relapsed/Refractory Multiple Myeloma (RRMM): A Real-World Observational Study
M Hultcrantz, D Kleinman, R Vij, F Escalante, N Kotowsky, J Bitetti, ...Blood 140 (Supplement 1), 1014-1016, 0
2
2022
Autoimmune diseases are not associated with monoclonal gammopathy of undetermined significance: results of the prospective population-based Istopmm study
IS Sverrisdottir, S Thorsteinsdóttir, S Rögnvaldsson, T Aspelund, ...Blood 140 (Supplement 1), 10031-1003, 0
2
2022
Clinical and translational results of the myeloma developing regimens using genomics (MyDRUG) sub-protocol C1 targeting RAS mutations
Clinical and translational results of the myeloma developing regimens using genomics (MyDRUG) sub-protocol C targeting RAS mutationsS Kumar, R Jayasinghe, G Bianchi, N Biran, M Hultcrantz, J Richter, R Vij, ...CLINICAL LYMPHOMA MYELOMA & LEUKEMIA 22, S29-S29, 2022202
1
2022
Modelling multiple time-scales with flexible parametric survival models
N Batyrbekova, H Bower, PW Dickman, A Ravn Landtblom, M Hultcrantz, ...BMC Medical Research Methodology 22 (), 290, 2022202
1
2022
A pilot plant based dietary intervention in MGUS and SMM patients with elevated BMI is feasible and associated with improvements in metabolic and microbiome biomarkers of …
UA Shah, A Derkach, F Castro, A Anuraj, J Blaslov, L Tran, PA Adintori, ...Blood 40 (Supplement ), 5066-5069, 2022202
1
2022
Stem Cell Autograft Minimal Residual Disease Negativity Improves Outcomes after Autotransplant for Multiple Myeloma
N Nishimura, S Brown, SM Devlin, PB Dahi, H Landau, OB Lahoud, ...Blood 40 (Supplement ), 620-622, 2022202
1
2022
Predicting the Need for Upfront Bone Marrow Sampling in Individuals with MGUS: Derivation of a Multivariable Prediction Model Using the Prospective Population-Based Istopmm Cohort
E Eythorsson, S Rögnvaldsson, S Thorsteinsdóttir, ER Reed, ...Blood 40 (Supplement ), 266-267, 2022202
1
2022
Monoclonal gammopathy of undetermined significance and risk of chronic kidney disease: results of the population-based Iceland screens, treats, or prevents multiple myeloma …
T Einarsson Long, E Eythorsson, S Rögnvaldsson, O Indridason, ...Blood 40 (Supplement ), 008-009, 2022202
1
2022
A randomized placebo controlled study of a plant-based dietary versus supplement versus placebo intervention in patients with monoclonal gammopathy of undetermined significance …
UA Shah, F Castro, A Anuraj, E Schach, A Derkach, NS Joseph, ...Blood 40 (Supplement ), 5052-5055, 2022202
1
2022

Referred From: https://scholar.google.com/citations?user=LhKADIIAAAAJ&hl=en

Cited by
Citations 4190
h-index 34
i10-index 59
Recommended Journals
Open Access Journals